TGFB1 and Hepatic fibrosis: Inhibiting the TGF-β type II receptor (TGFβR2) ameliorates liver fibrosis in experimental liver injury models, indicating TGF-β signaling as a viable pharmacological target [178]; (4) peroxisome proliferator-activated receptors (PPARs) take part in regulating lipid metabolism and reducing fibrosis.